SUMMARy
Cell salvage in obstetric haemorrhage is now endorsed by a number of organisations. Most of the literature has focused on isolated case series and safety. We describe how cell salvage, including a quality assurance process conducted prior to clinical implementation, was introduced to our stand-alone obstetric hospital which had no previous experience of this technique.
An implementation committee was established and 25 quality assurance and familiarisation cases were initially conducted. As part of this process the alpha fetoprotein, haematocrit, free plasma haemoglobin, potassium and Kleihauer tests were performed when enough blood was available for processing. Our guidelines for clinical use included women at greatly increased risk of obstetric haemorrhage and women at increased risk of haemorrhage who refused traditional transfusion. After the successful completion of this process, cell salvage was signed off for clinical use in March 2007 and was used on 51 occasions between March 2007 and July 2009. Twenty-one patients had salvaged blood re-transfused and for seven patients this was their only red blood cell replacement. The median blood loss in patients re-transfused was 3000 ml (range <500 to 8500 ml), with the median volume re-transfused 359 ml (range 60 to 1300 ml). There was one episode of unexplained hypotension associated with administration of salvaged blood.
We have successfully introduced obstetric cell salvage into clinical practice. A quality assurance process prior to implementation was beneficial for the staff involved. Despite targeting a high-risk obstetric population, our re-transfusion rates are approximately 40%. No serious adverse events have been recorded. We recommend that in units that already provide intraoperative cell salvage in a non-obstetric setting, extending the service into obstetric situations should be considered. Units that routinely care for high-risk obstetric patients should also consider the introduction of such a service. Post transfusion Kleihauer testing should be performed as soon as possible in Rhesusnegative mothers who deliver a Rhesus-positive foetus, so that appropriate anti-D prophylaxis can be administered.
The use of intraoperative cell salvage for obstetric haemorrhage is now endorsed by a number of professional organisations, including the Obstetric Anaesthetists Association 9 , the National Institute for Clinical Excellence 10 , the Association of Anaesthetists of Great Britain and Ireland 9 , the Confidential Enquiry into Maternal and Child Health 2 and the American College of Obstetricians and Gynecologists 11 . Indeed, the most recent Confidential Enquiry into Maternal and Child Health report 1 (2003 to 2005) suggests that, when women refuse transfusion of donated blood products, intraoperative cell salvage should be discussed and that "this facility should be provided for all women who give consent for this procedure". Clinical experience with cell salvage in obstetrics appears to be growing rapidly, with over 400 cases now reported in the literature 12 . Despite this, there is a significant lack of randomised trials in the obstetric population, due in part to the large numbers required to demonstrate both safety (approximately 265,000 patients 12 ) and decreased transfusion rates (approximately 4500 patients 6 ).
The current literature focuses mainly on safety, particularly the ability of the salvage process to remove contaminants and adverse clinical events, with little information about the development and implementation process of an obstetric cell salvage service 13 or practice guidelines. Our institution approved cell salvage for obstetric patients in March 2007 after a 12-month development and implementation process. This paper provides an overview of the development process, the guidelines implemented and the outcomes to date among our obstetric cohort, which were audited prospectively from the time of implementation. It may assist other units that are considering establishing an obstetric cell salvage service. Ethical approval for the publication of relevant patient data was obtained.
METHODS
King Edward Memorial Hospital for Women is a stand-alone women's hospital which provides tertiary obstetric services for a population of over two million and approximately 6500 deliveries per annum. Despite not having an on-site intensive care unit or interventional radiology, the hospital cares for most women in the region requiring high-risk obstetric and gynaecologic procedures. It is physically separated from other adult hospitals and prior to 2006, intraoperative cell salvage had not been available. In 2006, on the background of a dramatic increase in the number of deliveries per annum, the complexity of the caseload at this institution and with increasing evidence of the safety of cell salvage in the obstetric population, a multidisciplinary decision was taken to evaluate the possible introduction of cell salvage.
The implementation committee included an obstetrician, gynaecologist, anaesthetist, anaesthetic technician, perioperative nurse, haematologist and transfusion co-ordinator. In the absence of good evidence supporting the superiority of any particular cell salvage machine, a Haemonetics Cell Saver 5 (CS5, Haemonetics Corporation, Massachusetts, USA) was purchased. Although leucocyte depletion filters had been recommended and appeared important in the clearance of particulate matter such as foetal squames [13] [14] [15] , no manufacturer had endorsed their filter for use in obstetric haemorrhage. A Pall RS1 leucocyte depletion filter (Pall Medical, New york, USA), which is claimed to clear 99% of leucocytes and 82% of lipid particles, was chosen 16 .
Quality assurance and familiarisation process
Given the lack of previous experience and the safety concerns, a formal quality assurance process was instituted to assess the quality of the salvaged blood obtained. This process also allowed staff members to familiarise themselves with use of the cell saver and suction devices. In the absence of reports of a similar undertaking, we arbitrarily opted to include 25 cases in the initial pre-implementation evaluation on the basis that this appeared to be a reasonable number to gain clinical experience with the process and to gather laboratory data. It was decided that re-transfusion would not be performed during this phase.
As part of this process, an array of haematological tests were performed on the salvaged blood. These tests were conducted on the post-wash samples and after the passage of the blood through a leucocyte depletion filter. The tests included assays for alphafetoprotein (AFP), haematocrit (Hct), free plasma haemoglobin, serum potassium and the Kleihauer test. The rationale for these tests was that: 1) AFP is normally present in high concentration in the amniotic fluid and serum of neonates (less than 4000 kU/l and less than 80,000 kU/l respectively, compared with less than 250 kU/l in maternal serum at term). The AFP concentration in salvaged blood is an indicator of the quality of the washing process and the clearance of 'solute'; 2) the Hct reflects the red blood cell concentration in the salvaged blood, with manufacturers recommending target values of 40 to 50% 17 ; 3) the free plasma haemoglobin and potassium concentrations reflect the degree of red cell haemolysis occurring during salvage. Acceptable levels in salvaged blood have not been clearly defined, although it is expected that the washing process should Anaesthesia and Intensive Care, Vol. 38, No. 3, May 2010 remove more than 90% of free haemoglobin and potassium 18 ; 4) the Kleihauer test detects foetal red blood cells in maternal blood and the results are used to determine the appropriate dose of prophylactic Rhesus (D) immunoglobulin for administration to Rhesus (D) negative patients. Increased foetal red blood cell numbers in the salvaged blood sample provides an indication of potential risk of maternal immunisation to clinically significant foetal red cell antigens. Given that no previous quality assurance (QA) process had been described in the literature, we were unable to specifically define any benchmarks prior to the undertaking of this QA process. In this regard the results from each patient were reviewed by all members of the multidisciplinary team prior to signing off for clinical use.
Cell saver setup in the operating room
The major difference when dealing with obstetric patients compared with other surgical populations is the recommendation that a second, dedicated suction device be used for cell salvage, to decrease contamination of salvaged blood by amniotic fluid 14, 19 . We opted to use this suction device until uterine incision and again only after visual confirmation of removal of amniotic fluid from the surgical field. The blood salvaged from the surgical field is suctioned into a specific aspiration and anticoagulation assembly. This assembly, through the use of double lumen tubing and wall suction, mixes the aspirated blood, where it is drawn into the collection reservoir, with an anticoagulant solution (1000 ml 0.9% saline and 30, 000 IU heparin). The suction was set at 190 mmHg. Higher pressures (more than 200 mmHg) are not recommended by the manufacturer due to haemolysis of red blood cells 17, 20 . The CS5 was to be operated predominately in the automatic mode using a 125 ml Latham bowl.
Patient selection
The decision as to when intraoperative cell salvage will be provided is made after joint consultation between the obstetrician, anaesthetist and anaesthetic technician. Informed consent is obtained whenever possible and, as part of the introductory process, a specific patient information sheet and consent form were developed (available from the corresponding author on request). Rational patient selection is important in determining cost effectiveness and the sustainability of the service. We elected to reserve cell salvage for those women predicted to be at greatly increased risk of haemorrhage and for those at risk of haemorrhage but refused donor transfusions (Table 1) . Even if patients do not lose enough blood Table 1 The guidelines for patient selection for obstetric intraoperative cell salvage in our institution 1 Elective caesarean delivery with anticipated major haemorrhage, e.g. placenta accreta or percreta.
2 Elective caesarean delivery of patients who refuse donor blood transfusion and who are at increased risk of haemorrhage, e.g. a Jehovah's Witness with a risk factor for postpartum haemorrhage.
3 Acute postpartum haemorrhage (not from lower genital tract bleeding) requiring laparotomy (cell salvage dependent on the availability of accredited staff). to enable effective processing or warrant retransfusion, there are training and accreditation benefits for staff involved in the deployment and use of the equipment.
RESULTS
Of the initial 25 cases evaluated in the initial QA and familiarisation process, an insufficient volume of salvaged blood was obtained for processing and testing in 14. The results from the remaining 11 patients are summarised in Table 2 . After completion of this phase, clinical implementation proceeded and cell salvage has now been used for obstetric cases on 51 occasions between March 2007 to July 2009 (Table 3) , with nine cases conducted outside normal working hours and five proving useful only for teaching and training. Twenty-two women (43%) had salvaged blood processed by the cell salvage machine and of these, 21 women (41%) had salvaged blood re-transfused (median volume 359 ml, range 60 to 1300 ml) after an estimated median blood loss of 3000 ml (range <500 to 8500 ml) ( Table 4 ). Seven of 21 women (33%) received only salvaged red blood cells, but two of these seven women also received additional blood products (platelets or fresh frozen plasma) ( Table 4 ). Of the 14 women (66%) who did receive donor red cells, 11 had a preoperative haemoglobin of less than 120 g/l while the seven women who received cell salvaged blood only, all had a preoperative haemoglobin of greater than 120 g/l. Of the 30 women who did not receive salvaged blood, the median estimated blood loss was 750 ml (range <100 to 2000 ml) and four (13%) required donor red blood cell transfusion either intra-or postoperatively. The haemoglobin levels of patients in whom cell salvage was used (including patients in whom no blood was transfused) are shown in Table 5 .
The only adverse event associated with cell salvage was an episode of unexplained hypotension during the intraoperative transfusion of salvaged blood during a complex operation for placenta percreta. The episode was brief, transfusion of the salvaged blood was continued and the hypotension was easily corrected with intravenous phenylephrine.
DISCUSSION
In this paper we have described the introduction of cell salvage at a tertiary obstetric unit with no previous experience of its use. An innovative QA and familiarisation process was undertaken initially to allow possible modification of the planned approach. This process provided valuable initial experience for all operating room staff participating in preparation and maintenance of the cell saver equipment.
The contamination of salvaged blood by amniotic fluid and particulate matter has been the primary concern in obstetric haemorrhage. Amniotic fluid contains both solute and debris and the clearance of these contaminants by the cell saver varies 14 . The washing process can effectively remove the solute component (alpha-fetoprotein and active tissue factor) 7 but also removes plasma, platelets and most clotting factors 7 . The centrifuging process also removes some debris and the addition of a leucocyte depletion filter prior to re-transfusion clears particulate matter such as trophoblastic tissue, bacteria and some (but not all) foetal squamous cells 14 .
We believe that the QA and familiarisation process, which has not been described previously prior to implementation of cell salvage in obstetrics, proved valuable in training staff for the performance of intraoperative cell salvage and aided refinement of proposed clinical practice protocols. We did however, encounter some problems during the QA process. During the performance of the Kleihauer test (Kleihauer-Betke acid elution method), which was used to assess the foetal cell count in the salvaged blood, some of the initial samples were of poor quality and the salvaged cells were haemolysed during the staining process. This was thought to be due to factors such as sensitivity to the elution pH, time and temperature. As the trial progressed, sample quality improved, the salvaged cells showed improved morphology and the Kleihauer slides were satisfactory. The AFP levels were elevated in the QA samples in at least three cases (Table 2) , despite our efforts to avoid suctioning while amniotic fluid was present in the surgical field. This may have been secondary to deficiencies in the washing process, as in one case (case 11) the AFP, potassium and free haemoglobin were all elevated, although other explanations are possible. The familiarisation process also identified that low suction pressures were associated with slow clearance of blood from the surgical field and impaired visibility during periods of significant blood loss. The low suction pressure is recommended by the manufacturer 7 , although data from one previous study would suggest that higher suctions pressures (up to 300 mmHg) can be used during times of rapid blood loss with a small and likely clinically insignificant increase in the amount of haemolysis 20 . Since implementation we have used cell salvage regularly and in contrast to other units 13 , we opted to target women at the highest risk of obstetric haemorrhage (or its consequences). This includes the increasing number of women with an adherent placenta and Jehovah's Witness patients, both subpopulations having been represented in recent maternal mortality reports 1 . As a stand-alone hospital we require a dedicated cell saver technician and are not always able to provide a service, especially out of hours. The equipment costs are significant and include single-use consumables. Despite our selection criteria, in approximately 60% of cases retransfusion of salvaged blood was not possible or was not required. Others have shown that cell salvage can be cost-effective, because the cost of a single unit of banked blood exceeds that of the consumables 7 . Cell salvage also has the potential to reduce length of stay 21 and the amount of allogeneic blood used 22, 23 . Further cost savings can be achieved by initially setting up only equipment for the collection process (the aspiration and anticoagulation assembly), adding additional equipment only if sufficient blood is obtained for processing. Recent evidence also suggests a single suction device, with aspiration of the amniotic fluid, may be satisfactory 15 and might increase the volume of salvaged blood available in cases of anterior placenta praevia. We consider further evidence supporting safety is required before this approach is universally adopted.
Although cell salvage in obstetrics is growing in acceptance 12, [24] [25] [26] [27] , in our opinion until further evidence of clinical safety is available, there should be a good individual patient benefit versus risk assessment before giving salvaged blood and traditional transfusion triggers should be applied. Salvaged blood may contain foetal blood, which has maternal and paternal antigens. In our initial QA process, three samples demonstrated an increased foetal cell count when compared to the pre-procedure maternal sample. Re-transfusion of such blood might cause alloimmunisation to the paternal antigens expressed on the foetal red cells, with implications for future pregnancies. As yet there do not appear to be studies examining future pregnancy outcomes among women who have received obstetric cell salvage.
The results to date from our introductory period provide limited clinical information. We do not know the impact of cell salvage on our donor red blood cell transfusion rates but given that only seven patients had salvaged blood as their sole red cell transfusion, it is unlikely that the use of donor blood has reduced significantly. However, one patient who received salvaged blood in addition to donor red cells was a patient with a previously identified Anti Lub antibody who was classed as a 'difficult' cross-match and required selected antigen negative red cells. Using cell salvage in immunised patients may help reduce the load on the blood transfusion services that have to cater for these very specific requirements, often at limited notice. Among the seven patients in whom we performed cell salvage because they did not consent to donor transfusion, only one patient actually received salvaged blood. This supports the opinion that attention to surgical expertise is more important in avoiding major blood loss in these patients, although we also did have a lower threshold for utilising cell salvage in this patient population. Also of interest is the finding that in the 14 women who required donor red cell transfusion in addition to cell salvage blood, 11 (79%) had preoperative haemoglobin concentration of less than 120 g/l. In contrast, in all seven women who received cell salvaged blood only, preoperative haemoglobin was greater than 120 g/l ( Table 5 ). This would support the assertion that preoperative optimisation of high-risk patients may assist in reducing donor red cell requirements.
While we have endeavoured to provide a 24-hour cell salvage service in our institution, this has not been possible because of staff limitations. Some obstetric haemorrhage can be anticipated but a number of cases occur outside normal working hours. This was highlighted by a recently reported case in which a 36-year-old, gravida 2, para 2 woman required a perimortem caesarean delivery after collapsing at 31 weeks gestation due to blood loss from an undiagnosed placenta percreta 28 . During laparotomy she received 72 units of donor packed red blood cells as part of her transfusion requirements. Had we been able to provide an after-hours cell salvage service in this case, it is likely that we would have significantly decreased (but not eliminated) the volume of allogeneic blood that she received, with major benefits to a resource-limited blood transfusion service.
We have elected to operate the cell saver machine predominately in automatic mode, as recommended by the manufacturer 17 in this mode with the CS5 there are essentially five steps, the first being collection of blood. When using a 125 ml bowl, the CS5 will commence processing once 800 ml of fluid enters the reservoir. This salvaged solution is pumped into a spinning centrifuge bowl (Step 2) (default 5650 rpm for the 125 ml bowl) which separates the red cells from the supernatant, after which optical sensors detect whether the haematocrit is greater than 50% and if so, commence a cell washing cycle (Step 3) with 0.9% saline to remove contaminants such as free haemoglobin, platelets and other debris. On completion, the CS5 empties the washed cells into a reinfusion bag (Step 4) and these are available for re-transfusion to the patient via a leucocyte depletion filter. In high blood loss situations, the CS5 can be operated in an automated emergency mode that increases the speed at which the filling, washing and emptying steps are performed.
We consulted widely with the manufacturer and other user groups to determine an appropriate equipment setup for Jehovah's Witness patients. The acceptance of cell salvage by this patient population is often dependent on a guarantee of continuity of the circuit and their circulation 29 . First, this requires that all the components of the cell saver are assembled and primed with a non-blood solution, making the preliminary partial setup, as discussed above as a cost containment measure, inappropriate. The reinfusion line must also be primed, connected to the reinfusion bag and to the patient's intravenous access prior to salvage commencing.
Based on the endorsement of cell salvage in obstetric practice in the UK 2,9,10 , possible majority opinion favouring its use 26, 27 and our own experience, we offer the following advice. Where a service for other specialties is already provided, consideration should be given to extending this service for obstetric indications, given the apparent lack of detrimental outcomes, including no confirmed deaths to date. The Confidential Enquiry into Maternal and Child Health report highlights the potential life-saving value of cell salvage, especially in units dealing with patients who otherwise refuse blood transfusion and where massive obstetric haemorrhage is relatively common 2 . In units that do not routinely care for high-risk obstetric patients or have other surgical indications for cell salvage, we do not believe there is a compelling case to establish a service, given the costs and the low likelihood of re-transfusion. In units faced with caring for patients who refuse blood transfusion but in which no cell salvage service exists, the risk of bleeding should be evaluated on a case-by-case basis and those considered at high risk transferred to a centre with a service. If the degree of blood loss is such that the cell saver suction cannot maintain a clear surgical field, the suction pressure could potentially be increased up to 300 mmHg, accepting that more haemolysis is likely to occur. As the cell salvage process is unable to distinguish maternal and foetal red cells, in those Rhesus-negative women who are transfused with intraoperative cell salvaged blood that is potentially contaminated with red cells from a Rhesus-positive foetus, post transfusion Kleihauer testing should be performed as soon as possible and haematological advice obtained in regard to the most appropriate dose of prophylactic anti-D for the mother.
In conclusion, we have described the successful introduction of intraoperative cell salvage at a busy, stand-alone obstetric unit. Prior to clinical implementation we performed a quality assurance and familiarisation process to gain experience and refine protocols. Since its introduction, despite targeting our patients at highest risk, our re-transfusion rates have been approximately 40% and only one of seven patients who had refused to receive donated blood products required re-transfusion, highlighting the importance of surgical expertise in preventing blood loss in these cases. Irrespective of its endorsement for the management of obstetric haemorrhage, recommended transfusion triggers remain relevant and safety data are limited. Larger obstetric cohort data are needed and future studies should examine the impact of salvaged blood on alloimmunisation rates in cell salvage recipients.
